Light Chain Deposition Disease - 10 Studies Found
Active, not recruiting |
: Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease :
: |
Suspended |
: First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD :
: |
Active, not recruiting |
: Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects : Multiple Myeloma : 2009-11-16 : Device: Administering three additional MRI images Three additional MRI images to determine the role of c |
Completed |
: Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma :
|
Recruiting |
: Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma :
|
Completed |
: Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis :
: |
Terminated |
: HD Melphalan and SCT in Patients With IGDD or LCDD : Multiple Myeloma : 2008-05-18 :
|
Active, not recruiting |
: Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis :
|
Recruiting |
: Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma :
|
Completed |
: Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy :
|